The scientist’s investigation covers issues in Immunology, Transplantation, Graft-versus-host disease, Internal medicine and Hematopoietic stem cell transplantation. His research integrates issues of Disease and Stem cell in his study of Immunology. His research in Transplantation intersects with topics in Homologous chromosome, CD8, Vorinostat, Leukemia and Immunotherapy.
His work in the fields of Graft-versus-host disease, such as Extracorporeal Photopheresis, intersects with other areas such as Clostridia. Breast cancer, Prospective cohort study, Proportional hazards model and Nivolumab is closely connected to Oncology in his research, which is encompassed under the umbrella topic of Internal medicine. His Hematopoietic stem cell transplantation study combines topics in areas such as Gastroenterology, Haematopoiesis and Predictive value of tests.
Immunology, Graft-versus-host disease, Transplantation, Internal medicine and Hematopoietic stem cell transplantation are his primary areas of study. His studies link Disease with Immunology. His study looks at the relationship between Graft-versus-host disease and fields such as Cancer research, as well as how they intersect with chemical problems.
His Transplantation research integrates issues from Hematopoietic cell, Leukemia, Incidence and Hazard ratio. The Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology. The study incorporates disciplines such as Survival rate and Transplantation Conditioning in addition to Hematopoietic stem cell transplantation.
His scientific interests lie mostly in Internal medicine, Graft-versus-host disease, Oncology, Transplantation and Cell biology. His work in the fields of Internal medicine, such as Clinical trial, Breast cancer and Cohort, overlaps with other areas such as In patient. His Graft-versus-host disease research incorporates elements of Autophagy, ATG5, Hematopoietic stem cell transplantation and Immune system, Immunology.
He works mostly in the field of Immunology, limiting it down to topics relating to Microbiome and, in certain cases, Haematopoiesis, as a part of the same area of interest. His work in the fields of Autologous transplantation overlaps with other areas such as Context. His Cell biology study combines topics from a wide range of disciplines, such as T cell, Cytotoxic T cell and Secretion.
Pavan Reddy mostly deals with Internal medicine, Oncology, Breast cancer, Transplantation and Clinical trial. When carried out as part of a general Internal medicine research project, his work on Prostate cancer and Leukemia is frequently linked to work in Bone health and Context, therefore connecting diverse disciplines of study. His Oncology research incorporates themes from Cancer, Docetaxel, MEDLINE, Guideline and Randomized controlled trial.
His study in Transplantation focuses on Autologous transplantation in particular. Pavan Reddy has researched Clinical trial in several fields, including Acute graft versus host disease and Disease. His Disease research includes elements of Biomarker, Serum biomarkers and Serum samples.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
James L M Ferrara;John E Levine;Pavan Reddy;Ernst Holler.
The Lancet (2009)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Matthew T. Roe;Paul W. Armstrong;Keith A.A. Fox;Harvey D. White.
The New England Journal of Medicine (2012)
Acute graft-versus-host disease does not require alloantigen expression on host epithelium
Takanori Teshima;Rainer Ordemann;Pavan Reddy;Svetlana Gagin.
Nature Medicine (2002)
Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease.
Nathan D. Mathewson;Robert R Jenq;Anna V. Mathew;Mark Koenigsknecht.
Nature Immunology (2016)
Pathophysiology of graft-versus-host disease
James L.M. Ferrara;Pavan Reddy.
Seminars in Hematology (2006)
A biomarker panel for acute graft-versus-host disease
Sophie Paczesny;Sophie Paczesny;Oleg I Krijanovski;Thomas M Braun;Sung Won Choi.
ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
Mark T. Vander Lugt;Thomas M. Braun;Samir Hanash;Jerome Ritz.
The New England Journal of Medicine (2013)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson.
Journal of Clinical Oncology (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: